Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Milestone Pharmaceuticals Inc. (MIST : NSDQ)

• Company Description    Milestone Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing and commercializing the investigational new drug etripamil for the treatment of cardiovascular indications. The company's lead product candidate consists of MSP-2017, a nasal spray. Milestone Pharmaceuticals Inc. is based in Montr?al, Canada. Number of Employees: 29

• Price / Volume Information    Yesterday's Closing Price: $5.57 Daily Weekly Monthly 20 Day Moving Average: 65,078 shares Shares Outstanding: 29.92 (millions) Market Capitalization: $166.68 (millions) Beta: 3.11 52 Week High: $8.24 52 Week Low: $3.98 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -22.10% -12.27% 12 Week 3.72% 14.02% Year To Date -14.96% 0.36%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1111 DR. FREDERIK-PHILIPS BOULEVARD SUITE 420 - MONTREAL,A8 H4M 2X6 CAN ph: 514-336-0444 fax: - ir@milestonepharma.com http://www.milestonepharma.com

• General Corporate Information    Officers Joseph Oliveto - Chief Executive Officer Robert Wills - Chairman of the Board Amit Hasija - Chief Financial Officer Michael Tomsicek - Director Paul Truex - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 59935V107 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/10/22 Share - Related Items Shares Outstanding: 29.92 Most Recent Split Date: (:1) Beta: 3.11 Market Capitalization: $166.68 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.38 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.49 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/10/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.65 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -10.00% vs. Previous Quarter: 17.50% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -36.93 12/31/21 - -33.51 09/30/21 - -25.56 ROA 03/31/22 - -35.13 12/31/21 - -31.89 09/30/21 - -24.40 Current Ratio 03/31/22 - 22.77 12/31/21 - 17.55 09/30/21 - 22.70 Quick Ratio 03/31/22 - 22.77 12/31/21 - 17.55 09/30/21 - 22.71 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - -295.64 12/31/21 - -285.69 09/30/21 - -230.90 Book Value 03/31/22 - 3.37 12/31/21 - 3.77 09/30/21 - 4.27 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©